Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370813 | 1.00 | GPR119 (0.51) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL2371603 | 0.91 | GPR119 (0.50) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL2372010 | 0.89 | GPR119 (0.43) | GPR119KCNH2GPR183 | |
| SCHEMBL2371137 | 0.87 | GPR119 (0.60) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL2371173 | 0.86 | GPR119 (0.64) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL3204527 | 0.85 | GPR119 (0.65) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL15110124 | 0.85 | GPR119 (0.50) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL2371910 | 0.85 | GPR119 (0.44) | GPR119KCNH2 | |
| SCHEMBL15110022 | 0.84 | GPR119 (0.49) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL13195549 | 0.84 | GPR119 (0.71) | GPR119KCNH2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2611427-B1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARM INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170096398-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9365521-B2 | Non-hygroscopic salts of 5-HT2C agonists | ARENA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160151381-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9248133-B2 | Salts of lorcaserin with optically active acids | ARENA PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2013-11-28 | — | — | US | disclosed |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC | 2013-11-21 | — | — | US | disclosed |
| EP-2611433-A2 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611782-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030957-A2 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030938-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | GPR119 23/4885KCNH2 795/4885GPR183 240/4885 |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | GPR119 23/4885KCNH2 795/4885GPR183 240/4885 |
| US-20160151381-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | GPR119 4/4885KCNH2 556/4885GPR183 526/4885 |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | GPR119 23/4885KCNH2 795/4885GPR183 240/4885 |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | GPR119 23/4885KCNH2 795/4885GPR183 240/4885 |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | GPR119 4/4885KCNH2 556/4885GPR183 526/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | GPR119 23/4885KCNH2 795/4885GPR183 240/4885 |
| US-20170096398-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | GPR119 43/4885KCNH2 474/4885GPR183 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.